Satralizumab Alternatives Compared
Satralizumab | Soliris | Enspryng |
|
---|
Satralizumab | Soliris (eculizumab) | Enspryng (satralizumab) |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Neuromyelitis Optica Spectrum Disorder. satralizumab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Hemolytic Uremic Syndrome, Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder, Paroxysmal Nocturnal Hemoglobinuria. Soliris may also be used for purposes not listed in this... View more |
Prescription only
Prescribed for Neuromyelitis Optica Spectrum Disorder. Enspryng may also be used for purposes not listed in this medication guide. |
Related suggestions Neuromyelitis Optica Spectrum Disorder
|
|||||||||||||||
More about Satralizumab | More about Soliris (eculizumab) | More about Enspryng (satralizumab) | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Soliris has an average rating of 6.0 out of 10 from a total of 3 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 0% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: satralizumab side effects in more detail. |
See also: Soliris side effects in more detail. |
See also: Enspryng side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Soliris prices |
View all Enspryng prices |
||||||||||||||||
Dosage Forms Available | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
Enspryng | Other eculizumab brands include: Bkemv, Epysqli |
N/A |
||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
720 hours |
354 hours |
720 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 262 drugs are known to interact with satralizumab:
|
A total of 65 drugs are known to interact with Soliris:
|
A total of 262 drugs are known to interact with Enspryng:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
N/A |
March 16, 2007 |
N/A |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.